Creative Medical Technology Holdings Inc (CELZ)

[BillyBahama]

"Previous publications have demonstrated ability to selectively suppress harmful immune responses using complicated gene modification technology1," said Timothy Warbington, CEO. "The data disclosed suggest ability of ImmCelz® to achieve superior results in a manner which is amenable to rapid clinical translation."

"It is our goal to continue to bring our robust Allogenic Stem Cell programs through patent issue, thus creating a barrier of entry to competition, compilation of data for proof of concept, early stage trial(s) via FDA Investigational New Drug applications (IND) and to continue to seek out collaborators, potential licensees and/or joint venture partners from larger life science companies within our space," said Donald Dickerson, Chief Financial Officer of the company.

ImmCelz®
CaverStem®
FemCelz®
OvaStem®
StemSpine®
AmnioStem®
TregCelz™

https://www.biospace.com/article/releases/creative-medical-technology-holdings-reports-positive-preclinical-data-on-immcelz-immunotherapy-product-in-rheumatoid-arthritis-model/